Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

Dai Chihara, Chan Y. Cheah, Jason R. Westin, Luis E. Fayad, Maria A. Rodriguez, Fredrick B. Hagemeister, Barbara Pro, Peter Mclaughlin, Anas Younes, Felipe Samaniego, Andre Goy, Fernando Cabanillas, Hagop Kantarjian, Larry W. Kwak, Michael L. Wang, Jorge E. Romaguera*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Fingerprint Dive into the research topics of 'Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center'. Together they form a unique fingerprint.

Medicine & Life Sciences